| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.5 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.5 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |